Abstract 19231: N-acetylcysteine Inhibits Aortic Stenosis Progression in a Preclinical Murine Model

    loading  Checking for direct PDF access through Ovid

Abstract

Aortic stenosis (AS) is an age-related disease characterized by fibrotic aortic valve narrowing, resulting in high shear stress (SS). We demonstrated that SS can activate TGF-β1 released from platelets, and that N-acetylcysteine (NAC) partially inhibits SS-dependent platelet TGF-β1 activation in vitro. Here, we show that NAC blocks AS progression by inhibiting platelet TGF-β1 activation in an improved Ldlr-/-Apob100/100 (LDLR) spontaneous AS mouse model.

90%, as opposed to ~30% in the previously published model, of our LDLR mice (n=30) on a modified high-fat diet (HF) developed AS within 6 mo and showed >30% decreased cusp-separation (0.59 ± 0.02 vs. 0.86 ± 0.01; p<0.0001) and increased SS (328 ± 7 dyn/cm2 vs. 724 ± 50 dyn/cm2, p<0.0001) compared to basal levels. Valve thickness increased ~30% and collagen levels were >40% higher than basal levels. Total plasma TGF-β1 increased significantly and strongly correlated with SS (r=0.4, p=0.019). Physical association of activated platelets with valvular cells was seen, and the latter were also positive for p-Smad2 staining in nuclei, indicating that TGF-β1 is released from platelets and activated by SS.

To test whether blocking platelet TGF-β1 activation prevents AS progression, LDLR mice received pharmacological doses of NAC (2% in drinking water) at different stages of AS (mild to moderate at 3 mo and moderate to severe at 5 mo after HF). Significantly lower active TGF-β1 was generated after 2 h of SS and NAC treatments inhibited AS progression as seen by improved cusp separation (0.59 ± 0.02 in HF, 0.66 ± 0.02 at 3 mo NAC; 0.70 ± 0.02 at 5 mo NAC; p<0.05 for both NAC groups compared to HF) and SS (724 ± 50 dyn/cm2 in HF, 560 ± 38 dyn/cm2 at 3 mo NAC; 507 ± 28 dyn/cm2 at 5 mo NAC; p<0.05 for both NAC groups compared to HF), lower p-Smad2 (p=0.001) and valve thickness (p=0.02) compared to mice receiving HF alone.

Thus, results using our robust AS model suggest that shear-activated platelet TGF-β1 plays a critical role in the pathogenesis of AS progression. This model can be used for preclinical evaluation of preventative therapies, and assessing the benefits of NAC treatment in clinical trials.

Related Topics

    loading  Loading Related Articles